- No public price.
- Not disclosed
- Not disclosed
- —
- —
Pathology
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
On this page
16/100
Not rated: too little independent evidence yet.
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/6.6
No EHR integrations listed
- Evidence Strength8.4/28.8
1 peer-reviewed paper
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/5
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/4
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/2
None of the top-3 EHRs covered
- Peer-reviewed papers8/21
1 peer-reviewed paper
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Pricing transparency3/5
Pricing on request, no public amounts
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
No public price.
Evidence record
No FDA decision cited in our research as of November 2, 2026.
1 study on PubMed: 1 other, published 2026. Read the literature summary
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, Vesta record, https://medaiverdict.com/tools/valar-labs, version November 2, 2026
Bottom line
Vesta is sold as a laboratory service, not as software. A urologist orders it, the vendor says it is performed in Valar Labs' CLIA-certified laboratory, and the report arrives "approximately 3 days after the sample has arrived at our laboratory." It runs on routine H&E slides. Vesta Bladder (Risk Stratify and BCGPredict) is the main line, and the vendor also lists Vesta Prostate, whose orderability is not stated. Valar Labs has no FDA clearance on record, and the vendor mentions no Breakthrough designation. Urologists treating non-muscle-invasive bladder cancer are the target, and a pathology lab that wants to run the model in house is not.
How does the test work?
The platform behind Vesta is Computational Histology Artificial Intelligence, or CHAI. Valar says it was trained on "500,000+ annotations" from board-certified pathologists and built on "over 1,000 patients" with NMIBC. Orders go through a portal or a contact form. The CLIA number, CAP accreditation and EHR or LIS integration are not stated.
What do the results claim?
BCGPredict, in the vendor's words, is "the only bladder cancer diagnostic that predicts treatment response to BCG, through histology alone." Per the vendor, patients with the biomarker present carry twice the risk of non-response.
Risk Stratify returns recurrence and progression scores. By the vendor's account, a high recurrence score means twice the risk of high-grade recurrence over up to 24 months, and a high progression score means almost four times the risk of progression within 3 years. The clinical comparators in NMIBC are EORTC and CUETO risk tables and cystoscopy with pathology review.
Who is Valar Labs?
Valar Labs, Inc. was founded by Anirudh Joshi (CEO), Damir Vrabac (COO) and Viswesh Krishna (CTO). A $22 million Series A on May 22, 2024 was co-led by DCVC and a16z, with Pear VC participating. Headquarters and founding year are not stated.
What do the papers cover?
Fourteen papers carry a Valar affiliation, and those tied to Vesta and CHAI come from Valar authors. A 2025 Journal of Urology paper predicted response to intravesical BCG in high-risk NMIBC with the AI biomarker (PMID 39383345). A 2026 European Urology validation used the ANZUP trial cohort (PMID 42907292), and an external group may have been involved. A 2026 multi-center study in Cancers looked at changes in clinical management, not outcomes (PMID 41595169). Further 2025 papers cover BCG non-response and risk stratification of high-grade Ta disease, and other CHAI work spans muscle-invasive bladder, lung, colorectal and pancreatic cancer. Vesta Prostate is described in a 2026 JCO Precision Oncology paper.
How is access paid for?
Valar lists no price, and Medicare and insurance coverage are not stated. Its FAQ says the company "is committed to providing patient access regardless of finances" and describes a Financial Access Program for patients with financial needs.
The verdict
A urology practice treating high-risk NMIBC that is comfortable sending tissue to an outside lab can order Vesta, with BCG response prediction as the headline use. A hospital that wants the model running in its own lab, or needs an FDA-cleared test, has no route to either with Vesta.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. |
Source: vendor pricing page. Last checked November 2, 2026.
What the literature says
1 peer-reviewed study indexed on PubMed evaluate Vesta in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study. (opens in new tab)
- Packiam VT, Ghodoussipour S, Konety BR, et al.· Cancers (Basel)· 2026
- : Non-muscle invasive bladder cancer (NMIBC) management is increasingly complex due to conflicting guideline-based risk classifications, ongoing Bacillus Calmette-Guérin (BCG) shortages, and emerging alternative therapies. Computational Histology Artificial Intelligence (CHAI) tests are clinically available, providing insights from tumor specimens including predicting BCG responsiveness and individualized recurrence and progression risks, which may support precision medicine. This technology features biomarkers purpose-built for clinically unmet needs and has practical advantages includi…
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
No public price on the Tempus pages.|FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer)
PathAI AISight
by PathAI
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
No public price. Billing period, trial and refund not stated.|FDA 510(k)
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
No public price. Demo request only.|FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03)
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
No public price. Sold to laboratories and health systems on enterprise contracts.|FDA 510(k)